Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Feb 13 (Reuters) - Hofseth Biocare ASA HBC.OL: HOFSETH BIOCARE Q4 REVENUE NOK 72.2 MILLION HOFSETH BIOCARE Q4 EBITDA NOK -26.5 MILLION HOFSETH BIOCARE ASA - Q4 NET CASH FLOW NOK 1.57 MILLION DEMAND OUTLOOK FOR 2026 IS IMPROVING RAPIDLY Q4 PROFIT NOK -48.3 MILLION Q4 EPS NOK -0.12 Source text: ID:nGNEBBcFl Further company coverage: HBC.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hofseth Biocare ASA
See all newsBrief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand
Brief: Hofseth BioCare To Cancel Subsequent Offering
Brief: Hofseth Biocare Announces Results Of Subsequent Offering